trending Market Intelligence /marketintelligence/en/news-insights/trending/hatxnlv4tpf6zy7u7fyr9g2 content esgSubNav
In This List

Cancer Genetics gets Nasdaq noncompliance notice

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Cancer Genetics gets Nasdaq noncompliance notice

Rutherford, N.J.-based Cancer Genetics Inc. said it failed to comply with Nasdaq's $1 minimum bid price per share for its common shares.

The biotechnology company, which develops molecular and biomarker-based tests and services, has 180 calendar days, or until Feb. 4, 2019, to regain compliance.